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Abstract Cytomegalovirus (CMV) is an important
pathogen for both clinical and population settings. There
is a growing body of research implicating CMV in
multiple health outcomes across the life course. At the
same time, there is mounting evidence that individuals
living in poverty are more likely to be exposed to CMV
and more likely to experience many of the chronic
conditions for which CMV has been implicated. Further
research on the causal role of CMV for health and well-
being is needed. However, the strong evidence implicat-
ing CMV in type 2 diabetes, autoimmunity, cancer,
cardiovascular disease, vaccination, and age-related al-
terations in immune function warrants clinical and pub-
lic health action. This imperative is even higher among
individuals living in socioeconomically disadvantaged
settings and those exposed to high levels of chronic
psychosocial stress.
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Abbreviations
CAD Coronary artery disease
CVD Cardiovascular disease
GrB Granzyme B
NHANES National Health and Nutrition Examina-
tion Survey
RA Rheumatoid arthritis
SLE Systemic lupus erythematosus
T1D Type 1 diabetes
T2D Type 2 diabetes
WHAS Women’s Health and Aging Studies
CMVand pathologies of aging
Aging is characterized by a low-grade chronic inflam-
matory state, also called Binflammaging^ (Franceschi
et al. 2000), which represents a significant risk factor
for morbidity and mortality of elderly individuals as it is
implicated in the pathogenesis of several disabling dis-
eases of the elderly, including type 2 diabetes, osteopo-
rosis, Alzheimer’s disease, rheumatoid arthritis, and
coronary heart disease (Holmes et al. 2009; Isaacs
2009; Lindholm et al. 2008; Mundy 2007; Sarzi-
Puttini et al. 2005). Circulating inflammatory mediators
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such as cytokines and acute phase proteins are markers
of inflammaging. Among these, elevated serum levels
of IL-6 (2.6 pg/dL) and C-reactive protein (3.1–10 mg/
L) have been shown to predict 3-year mortality in the
elderly by the Invecchiare in Chianti study (Alley et al.
2007). The ways in which inflammaging contributes to
adverse health outcomes is still unclear, and therefore,
the identification of pathways controlling inflammaging
across multiple systems is important to understand, so
that interventions can be tailored to reduce
inflammaging potentially improving the health of elder-
ly individuals.
One of the driving forces of inflammaging is believed
to be chronic stimulation of immune cells with cyto-
megalovirus (CMV). CMV mainly infects fibroblasts;
epithelial, endothelial, and stromal cells; smooth muscle
cells (Haspot et al. 2012); and adipocytes (Bouwman
et al. 2008), which are believed to present CMVantigens
in the context of MHC class I. The inflammatory re-
sponse initiated by CMV-stimulated cells elicits the
release of pro-inflammatory cytokines secreted from
cells of the immune system and generates a vicious
cycle, leading to immune system remodeling. Briefly,
CMV induces the production of a variety of pro-
inflammatory mediators which in turn induce CMV
reactivation (Freeman 2009). In particular, in vitro stud-
ies have shown that CMV induces NF-kB activation in
HeLa cells, promoting the production of TNF-α which
leads to further activation of latent CMVand additional
upregulation of the inflammatory response (Prosch et al.
1995).
Several studies have shown clonal expansion of
CMV-specific T cells in seropositive elderly individuals
as well as associations of CMV seropositivity (or abso-
lute titers) with frailty, disability, and mortality. Howev-
er, conflicting reports exist in the literature, probably
due to the fact that anti-CMV IgG serology is a measure
that makes no distinction between recent and long-
established persistent infection. Moreover, there is also
evidence that high IgG levels are correlated with virus
reactivation and/or increased activity of the virus.
CMVand type 2 diabetes
Type 2 diabetes (T2D) is one of the most prevalent
chronic inflammatory diseases of the elderly. T2D in
the elderly represents 50% of total T2D cases and prev-
alence of T2D peaks at 15% in individuals 75 years of
age and older, suggesting that complications of T2D
increase with age (Smith-Palmer et al. 2014).
Immunosenescence and inflammaging are implicated
in the pathogenesis of T2D which in turn also alters
the immune response, and therefore, T2D elderly pa-
tients are more susceptible to infections as compared
with healthy age-matched controls.
Association of CMV seropositivity with pathogene-
sis of T2D was demonstrated in a cohort of individuals
85 years of age and older (Chen et al. 2012). Results
showed that CMV-seropositive individuals were at
higher risk of developing T2D, and had a higher level
of HbA1c and non-fasting glucose than CMV-
seronegative individuals, suggesting for the first time a
role for CMV infection in the pathogenesis of T2D in
very elderly but not in young individuals. This can be
explained by the fact that the direct deleterious effects of
CMVon pancreatic cells might have become significant
after a long period of CMV infection. Moreover, hyper-
glycemia has been shown to impair host defenses and
responses to infection, which may lead to higher sero-
prevalence of CMV in T2D patients (Geerlings and
Hoepelman 1999). Thus, higher prevalence of CMV
would be a result, not a cause, of disease. The fact that
CMV DNA can be detected in samples of pancreatic
tissue from patients with T2D strongly supports the
association of CMV with T2D (Lohr and Oldstone
1990). Human pancreatic β-cells have also been shown
to be susceptible to in vitro infection with CMV (Smelt
et al. 2012).
Retrospective studies have shown that CMVis one of
the most important causes of post-transplant morbidity
and mortality, due to increased allograft rejection, pre-
disposition to opportunistic infections, and also devel-
opment of post-transplant diabetes (Hjelmesaeth et al.
1997). An association between late-onset CMV infec-
tion and the development of post-transplant diabetes has
been shown (Leung Ki et al. 2008), and several mech-
anisms by which CMV may damage the pancreas have
been proposed, including (1) CMV-induced cytopathic
effects of β-cells and induction of apoptosis; (2) cyto-
toxic effects by infiltrating leukocytes; (3) induction of
pro-inflammatory cytokines caused by infection of β-
cells, neighboring pancreatic cells or infiltrating leuko-
cytes leading to alteredβ-cell function or apoptosis; and
(4) CMV-induced T cells crossreacting with β-cell
autoantigens and consequent killing of the β-cells
(Hjelmesaeth et al. 2005). The induction of pro-
inflammatory cytokines, together with the infiltration
of immune cells, is likely to provoke a strong and
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destructive immune response against the β-cells, al-
though experimental evidence still needs to be provided.
CMVand atherosclerotic cardiovascular complications
The association between CMV infection and atheroscle-
rotic cardiovascular disease (CVD) is well-known from
the literature (Blankenberg et al. 2001; Gkrania-Klotsas
et al. 2012; Muhlestein et al. 2000; Roberts et al. 2010;
Simanek et al. 2009, 2011; Spyridopoulos et al. 2016).
Since immunological processes are key features of ath-
erosclerosis, it has been postulated that CMV infection
increases cardiovascular mortality via immunological
mechanisms. In fact, CMV induces dramatic changes
in the human immune system, especially the T lympho-
cyte compartment, which exhibit many accelerated
aging-related changes in CMV-seropositive individuals
(Chidrawar et al. 2009; Wertheimer et al. 2014). CMV
has been identified in more than half of atherosclerotic
plaques, and CMV-positive plaques are associated with
increased numbers of macrophages and CD3+ T cells
(Yaiw et al. 2013). In addition, CMV drives both CD4+
and CD8+ T cell expansion toward terminal differenti-
ation such as CD4+CD28null cells and CD8+CCR7
−CD45RA+ TEMRA cells. These cells are highly cyto-
toxic and high in granzyme and perforin expression but
could simultaneously express high level of pro-
inflammatory cytokines including IFN-γ and TNF-α
(Chiu et al. 2016). Production of pro-inflammatory cy-
tokines in turn activates p38 in T cells, inhibits T cell
telomerase activity, and promotes loss of CD28 and T
cell differentiation, further creating a vicious cycle of
immunosenescence (Macaulay et al. 2013). CMV-
specific T cells are found to express high levels of
CX3CR1, which binds to injur ied vascular
endothelium-expressing fractalkine, and the β2-
adrenergic receptor, which permits rapid response to-
ward stress (Pachnio et al. 2016; van de Berg et al.
2012). It is important to note that not all persistent virus
infections result in terminally differentiated T cells. For
example, in CMV-seronegative individuals, herpes sim-
plex virus infection does not affect T cell subset homeo-
stasis significantly (Derhovanessian et al. 2011). At the
present, it is hypothesized that this difference is due to
the higher intensity and/or broad anatomical location of
sites from which CMV reactivates and/or generates an-
tigens for T cell stimulation, but that remains to be
experimentally addressed.
CMV seropositivity and elevated CRP, especially
when in combination, are strong predictors of mor-
tality in patients with coronary artery disease (CAD)
(Muhlestein et al. 2000). The association of CMV
infection with death is probably partially mediated
by chronic systemic inflammation. In a population-
based study involving 1468 participants, a composite
measure of TNF-α and IL-6 mediated a substantial
proportion of the association between CMV and all-
cause (18.9%, P < 0.001) and cardiovascular (29.0%,
P = 0.02) mortality (Roberts et al. 2010). A meta-
analysis based on 9000 CMV-infected individuals
and 8.608 controls from six prospective studies and
49 retrospective case-control studies showed that
CMV infection overall has an odds ratio of 1.67 for
CAD risk (Ji et al. 2012). The European Prospective
Investigation into Cancer (EPIC) study identified an
association between higher levels of CMV-IgG and
ischemic heart disease (with a hazard ratio of 1.4
when compared to seronegativity). Simanek et al.
reported significant associations between CMV infec-
tion and both CVD and CVD-related mortality in the
US population (Simanek et al. 2009, 2011). Similarly,
Roberts et al. showed that CMV was associated with
CVD mortality in a predominantly Latino population
living in the US and that these associations were
partly mediated by IL-6 (Roberts et al. 2010). Our
preliminary data among end-stage renal disease pa-
tients showed also the level of CMV-specific IgG
correlates with CVD in CMV-seropositive individ-
uals. In a multivariate model using CMV-IgG quintile
to predict existence of CAD, we found that CMV-IgG
quintile independently associates with concurrent
CAD (with an odds ratio of 2.1 when compared to
the lowest quintile). Obviously, different levels of
immune response toward CMV may pose higher
levels of risk for CMV-infected individuals.
CMVand autoimmune diseases
A link between CMVand autoimmune diseases is sug-
gested by several published data. A general point of
view is that CMV infection could cause and/or promote
autoimmune diseases, and CMV replication may en-
hance tissue damage caused by autoimmune patholo-
gies. On the other hand, autoimmunity-driven inflam-
matory processes are believed to support productive
infection rather than prevent viral reactivation and
growth.
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Rheumatoid arthritis Latent CMV infection influences
the clinical course and outcome of rheumatoid arthritis
(RA) (Davis et al. 2012; Pierer et al. 2012), and CMV
has been associated with more severe joint disease in
patients with RA (Rothe et al. 2016). Specific
immunopathogenic mechanisms through which CMV
could contribute to aggravation of joint damage in RA
patients include the expansion of CMV-specific CD4+
CD28− (Pawlik et al. 2003) and CD8+CD28− (Rothe
et al. 2016) T cells, which directly contribute to tissue
lesions.
The presence of miR-UL112-3p, the only circulating
CMVmicro-RNA (miR), has been shown in the plasma
of patients with RA (Mohammad et al. 2014). This miR
inhibits the translation of the CMV’s trans-activator
IE72, which impacts on active infection and might favor
maintenance of latency (Murphy et al. 2008). This miR
also targets cellular mechanisms involved in IL-32-
mediated TNF-α release, which may also affect the
establishment and maintenance of viral latency and
persistence (Huang et al. 2013).
Systemic lupus erythematosus Patients with systemic
lupus erythematosus (SLE) have higher frequencies of
CMV infection (Esen et al. 2012) as well as higher
CMV-specific IgG (Barzilai et al. 2007), and in those
SLE patients with higher CMV-specific IgG, higher
amounts of serum autoantibodies were detected
(Palafox Sanchez et al. 2009). In this last study, it was
also found that anti-CMV IgM positivity was associated
with lower levels of autoantibodies specific for U1RNP/
Sm and U1-70 k as compared to anti-CMV IgG positiv-
ity, suggesting a role for CMV reactivation in the regu-
lation of autoantibodies. Contrasting results have also
been reported with higher CMV-specific IgM, but sim-
ilar IgG, correlated with more severe disease activity
and autoantibodies in SLE patients (Su et al. 2007).
SLE patients often require immunosuppression to
induce remission of active disease symptoms, and these
patients are at higher risk of opportunistic infections. It
has indeed been shown that CMV seropositivity com-
plicated the course of SLE patients treated for disease
activity (Berman and Belmont 2017). These results
suggest that SLE patients undergoing aggressive immu-
nosuppressive treatments should be tested for IgGCMV.
A universal prophylaxis intervention management ap-
proach to decrease the risk of developing this potentially
life-threatening infection should be considered for
highest-risk patients.
Type 1 diabetes CMV DNA has been detected in
PBMCs of type-1 diabetes (T1D) patients, and a strong
correlation between CMV DNA and islet cell-specific
autoantibodies has been shown, suggesting that persis-
tent CMV infections may be relevant to the pathogenesis
of T1D (Pak et al. 1988). The diseasemay be the result of
an immune response to chronic exposure to either viral
antigens or cell-specific antigens in the context of MHC
class I and II overexpression (Bottazzo et al. 1985).
Association of CMV seropositivity with recurrence of
humoral and cellular autoimmunity to islet autoantigens
has also been shown in a T1D patient receiving a pan-
creas allograft (Zanone et al. 2010). Conversely, no
association between CMVand onset of T1D was found
in young children (Aarnisalo et al. 2008).
CMVand cancer CMV is not an oncogenic virus. How-
ever, CMV infection has been implicated in different
malignant diseases and the term Boncomodulation^ has
been conied to better explain that CMV infects tumor
cells and increases their malignancies (Michaelis et al.
2009). Detection of CMV DNA, mRNA, and/or anti-
gens in tumor tissues suggested a role of CMV infection
in the etiology of several human malignancies. Molec-
ular mechanisms of CMV-induced oncomodulation are
multiple and are summarized below.
CMV infection increases the ability of cancer cells to
evade immune surveillance. It has been reported that the
CMV proteins US2, US3, US6, and US11 decrease
expression of MHC class I on immune cells. Through
this mechanism, infected cancer cells avoid adaptive
immune response, in particular cytotoxic T cell re-
sponses (Lee et al. 2000). Also, the CMV-encoded
proteins UL16 and miR-UL112 downregulate MHC
class I expression. MHC class I-related UL16 proteins
are cellular ligands for the activating receptor NKG2D,
which is expressed on cytotoxic NK cells, γδ T cells,
and CD8+ cells (Wilkinson et al. 2008). Immune eva-
sion may also occur through production of immunosup-
pressive cytokines. The CMV-encoded viral IL-10 ho-
molog (UL111a; cmvIL-10) is a potent immunosuppres-
sive molecule, similar to human IL-10 (Kotenko et al.
2000).
CMV infection also increases the proliferative capac-
ity of cancer cells, and several CMV proteins, such as
the CMV-encoded chemokine receptor US28, have
been shown to promote cell cycle progression and cyclin
D1 expression in tumor cells (Maussang et al. 2006).
The CMV IE1 protein, which is detected in >90% of
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human mal ignant gl iomas, increases phos-
phatidylinositol 3-kinase/AKT activity (needed for cell
proliferation) and at the same time inactivates the tumor
suppressors Rb and p53 (promoting entry into S phase
of the cell cycle) (Cobbs et al. 2008).
Resistance to apoptosis is a common feature of can-
cer cells and represents a relevant mechanism of protec-
tion of cancer cells during chemotherapy (Hanahan and
Weinberg 2000; Pucci et al. 2000). CMV protects tumor
cells from apoptosis through the induction of several
intracellular signaling pathways such as AKT, mitogen-
activated protein kinase, and c-Jun NH2-terminal ki-
nase, following binding of CMV glycoproteins to
PDGFR or virus coreceptors [reviewed in (Cinatl et al.
2004; Michaelis et al. 2009)].
CMValso alters cancer cell invasion, migration, and
adhesion to the endothelium. CMV-infected neuroblas-
toma cells express increased adhesion to human endo-
thelial cells, occurring because CMV downregulates
neural cell adhesion molecule receptors in infected neu-
roblastoma cells, contributing to higher tumor cell ad-
hesion (Blaheta et al. 2004). Increased adhesion to the
endothelium has also been shown in human prostate
cancer cells (Blaheta et al. 2006). CMV is able to induce
interleukin 8 (IL-8), a promoter of tumor angiogenesis,
in leukemia and glioma cells, through NF-κB/AP-1-
mediated transactivation of the IL-8 promoter
(Murayama et al. 2000). CMV also suppresses the ex-
pression of angiogenesis inhibitors (thrombospondins)
in glioma cells (Cinatl et al. 1999).
CMVand frailty
Frailty, which is characterized by a state of decreased
physical activity and poor endurance, has been associ-
ated with clinical CVD (Bellumkonda et al. 2017). As a
result, it is possible that CMV infection also results in
frailty via chronic inflammation and/or CVD. Indeed,
CMV seropositivity was found to be associated with
frailty. In the Women’s Health and Aging Studies
(WHAS) (Wang et al. 2010), researchers found, after
having adjusted for age, history of smoking, BMI, DM,
and heart failure, that the odds ratio for frailty in persons
with CMV infection was 3.2. Furthermore, in persons
with high IL-6 level (>4.2 pg/mL), the adjusted odds
ratio for frailty in persons with CMV infection increased
to 20.3. Interestingly, in the BELFRAIL cohort, neither
CMV seropositivity nor CMV IgG titer was associated
with frailty in individuals aged 80 and older. The
observation might be due to survival effect because the
participants were only 70–79 years old in the WHAS
study and the BELFRAIL cohort recruited only people
older than 80. Another explanation could be the severity
of inflammation. A study performed in breast cancer
patients showed the IL-6 level significantly associated
with frailty, but the CMV status was not reported
(Brouwers et al. 2015). In long-term care geriatric pa-
tients, higher baseline hs-CRP and IL-6 levels were
associated with worse physical performance and gait
speed at 12 months independent of age and comorbidity
(Langmann et al. 2017). As a result, CMV infection
might only result in frailty or other deleterious health
conditions in individuals with high level of inflamma-
tion, but obviously further studies are needed to estab-
lish the solid link between CMVand frailty.
CMV, infectious diseases, and vaccine responses
Results on the effect of CMV seropositivity on influenza
vaccine responses are controversial with most of the
studies showing a negat ive effect of CMV
(Derhovanessian et al. 2013b, 2014; Frasca et al. 2015;
Trzonkowski et al. 2003) and others showing no effect
(den Elzen et al. 2011; Furman et al. 2015). The negative
effects of CMV seropositivity have been associated in
both elderly (Derhovanessian et al. 2013b; Frasca et al.
2015) and young (Frasca et al. 2015) individuals with the
presence of late differentiated/exhausted T cells (CD27
−CD28−CCR7−CD45RA+ or with CD28−CD57+),
which produce pro-inflammatory cytokines and have
therefore a significant role in age-related immune pathol-
ogies, suggesting that this virus may underlie rudimenta-
ry aspects of immunosenescence even in chronologically
young individuals (Turner et al. 2014). Results from a
recently published study have demonstrated that CMV
seropositivity negatively affects antibody response to the
influenza vaccine to a greater extent than inflammatory
markers, such as β2-microglobulin and IL-6, in older
adults (Reed et al. 2017). Conversely, the positive effects
of CMV seropositivity on the response to the influenza
vaccine have been shown only in young individuals
(Furman et al. 2015). In particular, it has been shown
that CMV-seropositive young individuals exhibited en-
hanced in vivo antibody responses, Th1 and Th2 re-
sponses, and cytotoxic T cell responses, as compared
with CMV-seronegative individuals, suggesting that
CMV can boost the immune response of young
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individuals and therefore shows features of a mutualistic
agent conferring benefits to the host.
When memory T cell responses to influenza antigens
were investigated, it was found that 40% of CMV-
seroposi t ive elderly, and 80% of the CMV-
seronegative elderly, had an influenza-specific CD4 T
cell response (Derhovanessian et al. 2014). The propor-
tion of young individuals mounting specific CD4 T cell
responses was comparable between seropositive and
seronegative individuals, suggesting that the effects of
CMVmay be only seen in the elderly because they have
been exposed to the virus for longer periods of time
(Derhovanessian et al. 2014). Moreover, the percentage
of individuals with CD8 T cell responses to influenza
antigens was lower than those with CD4, and this re-
sponse was not influenced by whether the subjects were
seropositive or seronegative. CMV-seropositive re-
sponders had significantly higher frequencies of late-
differentiated CD4 T cells (CD45RA+CCR7−CD27
−CD28−), as compared with CMV-infected non-re-
sponders (Derhovanessian et al. 2014). These late-
differentiated memory T cells, which are expanded in
elderly individuals, are specific for previously encoun-
tered CMVantigens (pp65 and IE1), and their presence
correlates with the ability to mount robust pro-
inflammatory responses against major CMV antigens
(TNF-α, IFN-γ, IL-17), suggesting that these cells are
positively associated with longer survival in elderly
individuals, and are at least partially functional and
necessary for further protection to subsequent infection
(Derhovanessian et al. 2013a).
CMV serostatus has been shown to be a key deter-
minant of the Granzyme B (GrB) response to influenza
challenge; CMV-seropositive subjects had low levels of
inducible GrB activity in response to influenza chal-
lenge (Haq et al. 2016), suggesting that CMV seropos-
itivity associated with a decline in GrB responses to
influenza may predict increased susceptibility to influ-
enza in older adults. CMV seropositivity has also been
shown to induce the expansion of polyfunctional CD8+
T cells (CD8+CD57+) secreting multiple cytokines
(IFN-γ, TNF-α), which can degranulate in response to
stimulation, and are therefore crucial for the generation
of optimal responses to infections and vaccines (Pera
et al. 2014). The authors of this study have suggested
that CMV seropositivity may provide protection against
some pathogens by keeping the immune system in a
state of alert. This could also explain its high prevalence
in humans.
CMV also impairs B cell responses to the influ-
enza vaccine, and a negative association between
CMV seropositivity and the B cell predictive bio-
markers of optimal vaccine responses has been
reported (Frasca et al. 2015). In this cohort,
CMV seropositivity has also been associated with
increased levels of systemic and B cell-intrinsic
inflammation, suggesting an additional mechanism
by which CMV downregulates the B cell antibody
response.
T2D is one of the chronic diseases where influenza
vaccination is recommended, and older adults with T2D
are less prone to influenza-induced clinical complica-
tions once vaccinated (Wang et al. 2013). The influenza
vaccine response was measured in T2D elderly individ-
uals and compared to healthy age-matched controls
(McElhaney et al. 2015). Results showed no differences
between T2D elderly and healthy elderly in the antibody
response to the vaccine. In this cohort, CMV did not
determine per se any functional alteration in clinical and
functional parameters of participating elderly individ-
uals. In the same study (McElhaney et al. 2015), the
antibody response to the vaccine was compared between
CMV-seropositive and CMV-seronegative elderly par-
ticipants. Results showed that both healthy and T2D
CMV-seropositive individuals had a significant higher
response, which was unexpected, suggesting that in
addition to age and diabetic status, immunological his-
tory such as CMV status should be taken into account.
Social and economic determinants that influence
CMV epidemiology and transmission
CMV infection has been considered a disease of poverty
and continues to be strongly patterned by socioeconomic
status in the US and globally (Hotez 2008; Manicklal
et al. 2013). Indeed, there is a substantial body of evi-
dence suggesting that CMV is socioeconomically (e.g.,
educational attainment and income) patterned across the
life course. For example, in 2009 Simanek et al. showed
that educational attainment was significantly associated
with seropositivity for CMVand that CMVinfection was
associated with CVD using data from the NHANES for
individuals ages 45 years and older (Simanek et al.
2009). In 2009 and 2012, Dowd et al. reported that
CMV seropositivity was higher among adults and chil-
dren with lower household income and educational
levels (using parental data on socioeconomic indicators
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for the children) (Dowd et al. 2009, 2012). More recent-
ly, using data from the Sacramento Area Latino study of
Aging, Meier et al. found that early-life socioeconomic
status influences adult probability of CMV infection and
that this association was mediated by measures of mid-
life socioeconomic status (Meier et al. 2016). In addition,
using data from NHANES, Feinstein et al. observed that
socioeconomic disparities in all-cause mortality in the
US were associated with CMV infection and that this
pathway was strongest among older individuals
(Feinstein et al. 2016). Further support for a role for
CMV in socioeconomic differentials in immunity was
demonstrated in a study byAiello et al., where CMVwas
found to be a significant mediator of the impact of
income on T cell markers of aging (Aiello et al. 2016).
Specifically, Aiello et al. showed that for every 10,000
decrease in income, there was a correspondingly signif-
icant decrease in effector to naïve T cell ratio for both
CD4 andCD8 cells and that the observed socioeconomic
differential in immunity was partially accounted for by
CMV seropositivity (Aiello et al. 2016). Of note, reduc-
tions in the proportion of naïve cells were associated with
lower income independent of effector cell proportions,
suggesting that these findings are not only explained by
an overall increase in effector cells. Nonetheless, further
research should include the total counts of each cell type
and subsets to examine whether income is associated
with absolute quantity of naïve and effector cell types.
The reasons why significant socioeconomic pat-
terning of CMVexists have not been fully elucidated.
The associations may reflect increased exposure to
CMV among individuals who are living in disadvan-
taged settings, which may be more likely to be char-
acterized by overcrowding, lack of access to hygiene
and sanitation resources, and increased use of
daycare at earlier ages, which have all been implicat-
ed in increased transmission of CMVas well as many
other infectious diseases (Hotez 2008; Manicklal
et al. 2013). At the same time, there is evidence that
individuals of lower socioeconomic status are bur-
dened by a higher force of CMV infection at earlier
ages, measured by the instantaneous per capita rate of
CMV acquisition by age (Colugnati et al. 2007).
Taken together, individuals experiencing greater so-
cioeconomic disadvantage not only have greater ex-
posure to CMV but also tend to experience signifi-
cantly higher rates of transmission of CMV and are
infected at an earlier age compared to individuals of
higher socioeconomic status.
There is also a growing body of literature demon-
strating consistent associations between socioeconomic
disadvantage and other psychosocial stressors and CMV
antibody levels (Aiello et al. 2010). In response to
exposure to stressors, human immunity may be altered,
providing an opportunity for CMV to replicate and
circulate, in turn inducing production of CMV-specific
IgG antibodies (Rector et al. 2014). For these reasons,
higher CMV IgG antibody levels have been used as a
surrogate measure of stress-related altered cell-mediated
immunity in several studies (Segerstrom and Miller
2004). For example, higher CMV antibody levels have
been noted in response to exam stress, space flight, and
loneliness (Jaremka et al. 2013, 2014; Mehta et al. 2000;
Sarid et al. 2001). Other studies have identified associ-
ations between socioeconomic status and CMV IgG
antibody levels. In 2008, Dowd et al. showed that lower
educational attainment was associated with significantly
higher antibody response to CMVamong older Latinos
in the US (Dowd et al. 2008). Using data from
NHANES, Dowd et al. demonstrated an association
between lower income and education with higher
CMV IgG antibody levels in the US population
(Dowd and Aiello 2009). These findings also held for
children living in US households with income below the
poverty line (Dowd et al. 2012).
Aiello et al. used data from the Multi-Ethnic Study
of Atherosclerosis and showed that chronic exposure
to stressors resulted in a higher antibody response to
CMV along with several other persistent pathogens,
suggesting that exposure to stressors might influence
not only CMV but also other persistent pathogens,
including other herpesviruses and chronic bacterial
species (Aiello et al. 2009). In 2014, Rector et al.
reported associations between measures of psycho-
logical well-being (depression, vital exhaustion, and
poorer mental health) with higher CMV antibodies in
an occupational cohort in Germany, and these asso-
ciations were shown to be more robust among those
of lower socioeconomic status (Rector et al. 2014).
Together, these studies indicate that socioeconomic
status and other psychosocial stressors may modify
CMV IgG antibody response in humans. Further
research regarding the extent to which CMV IgG
antibody levels rise and persist in response to
stressors is needed. Moreover, research exploring
the variability in CMV IgG immune response to
acute versus chronic exposure to stressors is warrant-
ed. Finally, there is little research on the age-related
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differences in CMV IgG antibody response to
stressors, making it difficult to identify whether ex-
posure to stressors at certain age periods are more or
less detrimental to CMV immunity and age-related
alterations in immune function.
Future needs and avenues
This review identified multiple clinical and epidemi-
ological studies supporting associations between
CMV and chronic conditions, including T2D, auto-
immune conditions, CVD, frailty, vaccination re-
sponse, and age-related alterations in immune func-
tion and inflammation. At the same time, there is a
growing body of research suggesting that socioeco-
nomic status and other psychosocial stressors influ-
ence CMV infection and IgG antibody response. To-
gether, this work indicates that CMV may have pleio-
tropic influences on health that vary by age and
socioeconomic status. Further work integrating both
the social and clinical patterning of CMV is needed.
Moreover, there is a need to better understand how
factors such as timing of CMV infection, infectious
dose, and reactivation of CMV over time influence
health and well-being. Research examining methods
for dampening CMV immune response in aging pop-
ulations is needed to better define the associations
between CMV and vaccination efficacy. The causal
link to the many exposures and outcomes that we
have reviewed here is still debatable. Nonetheless,
the body of evidence suggests that CMV is an impor-
tant culprit for many critical exposures and health
outcomes, warranting a more urgent clinical and pub-
lic health response to research and intervention stud-
ies that can clarify the role and extent to which
removing CMV infection and altering its influence
on age-related immunity may protect and reduce the
burden of many diseases that are common and in-
creasing in the population. Future studies should
consider research on vaccinations and interventions
to cut down on the transmission of CMV in human
populations, especially among individuals living in
lower socioeconomic settings and early in life when
CMV infection is common.
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